Drug firm Unichem Laboratories on Tuesday said it has received approval from the US health regulator to market its Cyclobenzaprine Hydrochloride tablets used for relief of muscle spasm in the American market.
The company has received abbreviated new drug application (ANDA) approval to market its Cyclobenzaprine Hydrochloride tablets USP 5 mg, 7.5 mg and 10 mg from the United States Food and Drug Administration (USFDA), Unichem Labs said in a filing to the BSE.
Also read: Zydus Cadila gets nod from Mexico to test Covid-19 drug
The product is a generic version of Janssen Research and Development LLC’s Flexeril tablets, it added. The tablets will be commercialised from the company’s Goa plant, Unichem Labs said.
Cyclobenzaprine Hydrochloride tablets are indicated for the treatment as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions, it added. Shares of Unichem Labs on Tuesday closed 3.33 per cent higher at Rs 189.10 per scrip on the BSE.
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
